EA200700210A1 - ВАРИАНТЫ ОБЛАСТИ Fc - Google Patents

ВАРИАНТЫ ОБЛАСТИ Fc

Info

Publication number
EA200700210A1
EA200700210A1 EA200700210A EA200700210A EA200700210A1 EA 200700210 A1 EA200700210 A1 EA 200700210A1 EA 200700210 A EA200700210 A EA 200700210A EA 200700210 A EA200700210 A EA 200700210A EA 200700210 A1 EA200700210 A1 EA 200700210A1
Authority
EA
Eurasian Patent Office
Prior art keywords
region
options
altered
provides
polypeptide
Prior art date
Application number
EA200700210A
Other languages
English (en)
Other versions
EA012464B1 (ru
Inventor
Барретт Аллан
Вэйдун Цзян
Ин Тан
Джеффри Дин Уоткинс
Original Assignee
Эпплайд Молекьюлар Эволюшн, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эпплайд Молекьюлар Эволюшн, Инк. filed Critical Эпплайд Молекьюлар Эволюшн, Инк.
Publication of EA200700210A1 publication Critical patent/EA200700210A1/ru
Publication of EA012464B1 publication Critical patent/EA012464B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

В настоящем изобретении предлагаются полипептиды, особенно терапевтические антитела, которые включают новый вариант области Fc. Кроме того, в изобретении предлагаются варианты области Fc, которые обеспечивают измененную эффекторную функцию или измененный период полужизни в сыворотке полипептида, с которым они функционально связаны.
EA200700210A 2004-08-04 2005-07-18 Антитело против cd20 и его применение EA012464B1 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US59885504P 2004-08-04 2004-08-04
US60295304P 2004-08-19 2004-08-19
US60433904P 2004-08-25 2004-08-25
US60910104P 2004-09-10 2004-09-10
US63844204P 2004-12-23 2004-12-23
US64371805P 2005-01-13 2005-01-13
PCT/US2005/025276 WO2006020114A2 (en) 2004-08-04 2005-07-18 Variant fc regions

Publications (2)

Publication Number Publication Date
EA200700210A1 true EA200700210A1 (ru) 2007-08-31
EA012464B1 EA012464B1 (ru) 2009-10-30

Family

ID=35276048

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700210A EA012464B1 (ru) 2004-08-04 2005-07-18 Антитело против cd20 и его применение

Country Status (16)

Country Link
US (1) US7740847B2 (ru)
EP (2) EP1776384B1 (ru)
JP (2) JP5055603B2 (ru)
KR (1) KR100864549B1 (ru)
CN (1) CN101001873B (ru)
AU (1) AU2005274905B2 (ru)
BR (2) BRPI0514068B8 (ru)
CA (2) CA2573192C (ru)
DK (2) DK2213683T3 (ru)
EA (1) EA012464B1 (ru)
ES (2) ES2426816T3 (ru)
IL (1) IL180885A0 (ru)
MX (1) MX2007001345A (ru)
NO (1) NO339556B1 (ru)
PL (2) PL2213683T3 (ru)
WO (1) WO2006020114A2 (ru)

Families Citing this family (241)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
EP2270147B2 (en) 1999-04-09 2020-07-22 Kyowa Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
AU2002236517A1 (en) * 2000-11-29 2002-06-11 University Of Southern California Targetet retoviral vectors for cancer immunotherapy
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1587540B1 (en) 2003-01-09 2021-09-15 MacroGenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
EP2353389B1 (en) * 2003-04-21 2015-11-04 Epeius Biotechnologies Corporation Compositions for treating disorders
US20090123428A1 (en) * 2003-04-21 2009-05-14 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
JP2007503206A (ja) 2003-08-22 2007-02-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 変更されたエフェクター機能を有する改良された抗体およびその抗体を産生する方法
US7521542B2 (en) 2004-05-10 2009-04-21 Macrogenics, Inc. Humanized FcγRIIB-specific antibodies and methods of use thereof
WO2006085967A2 (en) * 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
EP2399936A3 (en) 2004-07-26 2012-02-22 Biogen Idec MA Inc. Anti-CD154 antibodies
BRPI0514068B8 (pt) 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
DK2325207T3 (en) * 2004-11-12 2017-06-06 Xencor Inc Fc variants with altered binding to FcRn
US20100104564A1 (en) * 2005-03-29 2010-04-29 Genevieve Hansen Altered Antibody Fc Regions and Uses Thereof
EP3479844B1 (en) 2005-04-15 2023-11-22 MacroGenics, Inc. Covalent diabodies and uses thereof
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US8309690B2 (en) * 2005-07-01 2012-11-13 Medimmune, Llc Integrated approach for generating multidomain protein therapeutics
WO2007008943A2 (en) * 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
ES2579602T3 (es) 2005-08-10 2016-08-12 Macrogenics, Inc. Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de uso de estos
CA2625619A1 (en) 2005-10-14 2007-04-26 Medimmune, Inc. Cell display of antibody libraries
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
CN105177091A (zh) 2006-03-31 2015-12-23 中外制药株式会社 用于纯化双特异性抗体的抗体修饰方法
EP2032159B1 (en) 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
PT2029173T (pt) 2006-06-26 2016-11-02 Macrogenics Inc Anticorpos específicos fc rib e seus métodos de uso
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
EP2121756A4 (en) 2006-12-20 2011-08-31 Mmrglobal Inc ANTIBODIES AND PROCESS FOR THEIR PREPARATION AND USE
AU2013202392B2 (en) * 2006-12-20 2016-02-25 Mmrglobal, Inc. Antibodies and methods for making and using them
AU2008232409C1 (en) 2007-03-22 2013-12-05 Biogen Ma Inc. Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof
WO2008137915A2 (en) 2007-05-07 2008-11-13 Medimmune, Llc Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
JP2010535032A (ja) 2007-07-31 2010-11-18 メディミューン，エルエルシー 多重特異性エピトープ結合性タンパク質およびその用途
WO2009026177A1 (en) 2007-08-17 2009-02-26 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
WO2009117030A2 (en) 2007-12-19 2009-09-24 Macrogenics, Inc. Improved compositions for the prevention and treatment of smallpox
MX343594B (es) 2007-12-21 2016-11-11 Medimmune Ltd Miembros de union para receptor alfa de interleucina-4 (il-4ra) - 173.
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
BRPI0821604B1 (pt) 2007-12-26 2021-09-21 Xencor, Inc Polipeptídeo isolado compreendendo um fc variante de polipeptídeo de fc de igg humano, método para produzir o mesmo e uso de anticorpo
JP2011509675A (ja) 2008-01-18 2011-03-31 メディミューン，エルエルシー 部位特異的コンジュゲーションのためのシステイン操作抗体
ES2654937T3 (es) 2008-04-02 2018-02-15 Macrogenics, Inc. Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos
PT2247304T (pt) 2008-04-02 2016-08-29 Macrogenics Inc Anticorpos especificos de her2/neu e métodos de utilização dos mesmos
NZ588507A (en) 2008-04-11 2012-11-30 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
EP2280997A2 (en) * 2008-04-18 2011-02-09 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
KR20110033233A (ko) * 2008-07-21 2011-03-30 이뮤노메딕스, 인코오포레이티드 개선된 치료 특성을 갖는 항체의 구조 변이체
RU2536937C2 (ru) * 2008-10-14 2014-12-27 Дженентек, Инк. Варианты иммуноглобулина и их применения
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
CA2766405A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc Engineered fc regions for site-specific conjugation
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
MX2012004029A (es) 2009-10-07 2012-05-08 Macrogenics Inc Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso.
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
NZ602161A (en) 2010-03-04 2014-12-24 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
CN103154025B (zh) 2010-08-02 2015-07-01 宏观基因有限公司 共价双抗体及其用途
JP2013537416A (ja) 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
WO2012032080A1 (en) 2010-09-07 2012-03-15 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Stabilised human fc
EP2614085B1 (en) 2010-09-10 2016-04-20 Apexigen, Inc. Anti-il-1 beta antibodies and methods of use
US20120164137A1 (en) * 2010-10-20 2012-06-28 Morphotek, Inc. Anti-folate receptor alpha antibody glycoforms
CN107973851A (zh) 2010-11-30 2018-05-01 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
CN109160951A (zh) 2010-11-30 2019-01-08 中外制药株式会社 细胞毒诱导治疗剂
ES2634098T3 (es) 2011-01-14 2017-09-26 The Regents Of The University Of California Anticuerpos terapéuticos contra la proteína ROR-1 y procedimientos para el uso de los mismos.
CA2827170A1 (en) 2011-02-11 2012-08-16 David M. Hilbert Monovalent and multivalent multispecific complexes and uses thereof
WO2012115241A1 (ja) 2011-02-25 2012-08-30 中外製薬株式会社 FcγRIIb特異的Fc抗体
EP2681243B1 (en) 2011-03-03 2018-09-05 Apexigen, Inc. Anti-il-6 receptor antibodies and methods of use
WO2012122513A2 (en) 2011-03-10 2012-09-13 Omeros Corporation Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
CA2828289C (en) * 2011-03-29 2020-07-21 Roche Glycart Ag Antibody fc variants
EP3415528B1 (en) 2011-04-13 2021-05-26 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
WO2012149356A2 (en) 2011-04-29 2012-11-01 Apexigen, Inc. Anti-cd40 antibodies and methods of use
JP6145088B2 (ja) 2011-05-21 2017-06-07 マクロジェニクス，インコーポレーテッド 脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
CN109517059B (zh) 2011-06-30 2023-03-28 中外制药株式会社 异源二聚化多肽
UA117901C2 (uk) * 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
JP5944994B2 (ja) 2011-08-12 2016-07-05 オメロス コーポレーション 抗ｆｚｄ１０モノクローナル抗体およびそれらの使用方法
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
WO2013047752A1 (ja) * 2011-09-30 2013-04-04 中外製薬株式会社 抗原の消失を促進する抗原結合分子
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
RU2722829C9 (ru) 2011-09-30 2020-09-22 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула, индуцирующая иммунный ответ на антиген-мишень
BR112014007487A2 (pt) 2011-09-30 2017-04-04 Dana Farber Cancer Inst Inc peptídeos terapêuticos
EP2787078B1 (en) 2011-10-31 2019-05-22 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
EP2785742B1 (en) 2011-11-02 2020-01-08 Apexigen, Inc. Anti-kdr antibodies and methods of use
EP2776061B1 (en) 2011-11-07 2019-08-14 MedImmune, LLC Multispecific and multivalent binding proteins and uses thereof
US20150056182A1 (en) 2011-11-30 2015-02-26 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
WO2013093809A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
KR102041412B1 (ko) * 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
JP6138108B2 (ja) 2012-02-24 2017-05-31 中外製薬株式会社 ＦｃγＲＩＩＢを介して抗原の消失を促進する抗原結合分子
JP6280031B2 (ja) 2012-03-29 2018-02-14 中外製薬株式会社 抗ｌａｍｐ５抗体およびその利用
ES2856272T3 (es) 2012-05-30 2021-09-27 Chugai Pharmaceutical Co Ltd Molécula de unión a antígenos para eliminar antígenos agregados
CA2874721A1 (en) 2012-05-30 2013-12-05 Tomoyuki Igawa Target tissue-specific antigen-binding molecule
EP2869845B1 (en) * 2012-07-06 2019-08-28 Genmab B.V. Dimeric protein with triple mutations
PT2869845T (pt) * 2012-07-06 2019-12-09 Genmab Bv Proteína dimérica com mutações triplas
RS57704B1 (sr) 2012-07-13 2018-12-31 Roche Glycart Ag Bispecifična anti-vegf/anti-ang-2 antitela i njihova primena u lečenju vaskularnih bolesti oka
US10919953B2 (en) * 2012-08-24 2021-02-16 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific Fc region variant
EP3597747B1 (en) 2012-08-24 2023-03-15 Chugai Seiyaku Kabushiki Kaisha Mouse fcgammarii-specific fc antibody
WO2014070934A1 (en) 2012-10-30 2014-05-08 Apexigen, Inc. Anti-cd40 antibodies and methods of use
NZ706377A (en) 2012-11-08 2019-06-28 Eleven Biotherapeutics Inc Il-6 antagonists and uses thereof
EA201590783A1 (ru) 2012-11-15 2015-11-30 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
HUE047874T2 (hu) 2012-12-10 2020-05-28 Biogen Ma Inc Vér dendritikus sejt antigén 2 elleni antitestek és alkalmazásuk
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
EP4119947A1 (en) 2012-12-21 2023-01-18 Chugai Seiyaku Kabushiki Kaisha Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
CN105102618B (zh) 2012-12-27 2018-04-17 中外制药株式会社 异源二聚化多肽
EA201500741A1 (ru) * 2013-01-10 2016-01-29 Генмаб Б.В. ВАРИАНТЫ Fc-ОБЛАСТИ IGG1 ЧЕЛОВЕКА И ИХ ПРИМЕНЕНИЕ
ES2813501T3 (es) 2013-02-12 2021-03-24 Bristol Myers Squibb Co Métodos de replegado de proteínas basados en filtración de flujo tangencial
ES2751735T3 (es) 2013-02-12 2020-04-01 Bristol Myers Squibb Co Métodos de replegado de proteínas a elevado pH
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
ES2882183T3 (es) 2013-03-14 2021-12-01 Univ Duke Moléculas biespecíficas que son inmunorreactivas con células efectoras inmunitarias que expresan un receptor activador
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
CN105378075B (zh) 2013-03-15 2022-04-05 Atyr 医药公司 组氨酰-trna合成酶-fc缀合物
EA201591559A1 (ru) 2013-03-15 2016-03-31 Дана-Фарбер Кэнсер Инститьют, Инк. Терапевтические пептиды
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
AU2014236986A1 (en) 2013-03-15 2015-09-03 Biogen Ma Inc. Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
BR112015023752B1 (pt) 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
KR20210130260A (ko) 2013-04-02 2021-10-29 추가이 세이야쿠 가부시키가이샤 Ｆｃ영역 개변체
JPWO2014208482A1 (ja) 2013-06-24 2017-02-23 中外製薬株式会社 ヒト化抗Ｅｐｉｒｅｇｕｌｉｎ抗体を有効成分として含む腺癌以外の非小細胞肺癌の治療剤
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
AU2014312190A1 (en) 2013-08-28 2016-02-18 Bioasis Technologies Inc. CNS-targeted conjugates of antibodies
CN118005782A (zh) 2013-10-02 2024-05-10 免疫医疗有限责任公司 中和抗甲型流感抗体及其用途
WO2015057939A1 (en) 2013-10-18 2015-04-23 Biogen Idec Ma Inc. Anti-s1p4 antibodies and uses thereof
CN105636924B (zh) 2013-10-18 2018-08-07 德国癌症研究中心 前列腺特异性膜抗原(psma)的标记的抑制剂，它们作为显影剂和用于治疗前列腺癌的药剂的用途
CN105980557B (zh) 2013-12-04 2020-04-07 中外制药株式会社 抗原结合能力根据化合物的浓度而变化的抗原结合分子及其文库
US10106611B2 (en) 2013-12-06 2018-10-23 Dana-Farber Cancer Institute, Inc. Antibodies that bind to MHC class I polypeptide-related sequence A
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
EP3925973A1 (en) 2014-03-14 2021-12-22 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers
SG11201607434WA (en) 2014-04-07 2016-10-28 Chugai Pharmaceutical Co Ltd Immunoactivating antigen-binding molecule
EP3141603A4 (en) 2014-05-08 2017-12-27 Chugai Seiyaku Kabushiki Kaisha Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
US11505605B2 (en) 2014-05-13 2022-11-22 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
EP3142700B1 (en) 2014-05-16 2021-03-03 Medimmune, LLC Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
LT3151921T (lt) 2014-06-06 2019-12-10 Bristol Myers Squibb Co Antikūnai prieš gliukokortikoidu indukuojamą naviko nekrozės faktoriaus receptorių (gitr) ir jų panaudojimas
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
JP6932639B2 (ja) 2014-09-29 2021-09-08 デューク ユニバーシティ Ｈｉｖ‐１エンベロープ標的化アームを備える二重特異性分子
CA2965689C (en) 2014-11-07 2022-03-22 Eleven Biotherapeutics, Inc. Improved il-6 antibodies
WO2016081746A2 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３に対する抗体およびその使用
AR103162A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y métodos para su uso
CN107108726A (zh) 2014-12-19 2017-08-29 中外制药株式会社 抗‑肌肉生长抑制因子抗体、包含变体fc区的多肽及使用方法
CN107207594B (zh) 2014-12-23 2019-05-07 百时美施贵宝公司 针对tigit的抗体
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
SG11201706014PA (en) 2015-02-05 2017-08-30 Chugai Pharmaceutical Co Ltd Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
AU2016246426B2 (en) 2015-04-06 2020-11-12 Arcellx, Inc De novo binding domain containing polypeptides and uses thereof
KR20180010264A (ko) 2015-05-29 2018-01-30 브리스톨-마이어스 스큅 컴퍼니 Ox40에 대한 항체 및 그의 용도
EP3322735A4 (en) 2015-07-15 2019-03-13 Zymeworks Inc. BISPECIFIC ANTIGEN-BINDING CONSTRUCTS CONJUGATED TO A MEDICINAL PRODUCT
TWI751300B (zh) 2015-09-18 2022-01-01 日商中外製藥股份有限公司 Il-8 結合抗體及其用途
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
WO2017086419A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 液性免疫応答の増強方法
SG11201803817PA (en) 2015-11-19 2018-06-28 Bristol Myers Squibb Co Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
MA43365A (fr) * 2015-12-01 2018-10-10 Genmab Bv Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3398965A4 (en) 2015-12-28 2019-09-18 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PROMOTING THE EFFICACY OF PURIFYING A POLYPEPTIDE CONTAINING AN FC REGION
KR20180116359A (ko) 2016-02-23 2018-10-24 세센 바이오, 아이엔씨. 인터루킨-6의 길항제 제제 및 이의 용도
JP2019514844A (ja) 2016-03-04 2019-06-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｃｄ７３抗体を用いた併用療法
SG11201807936VA (en) 2016-03-14 2018-10-30 Chugai Pharmaceutical Co Ltd Cell injury inducing therapeutic drug for use in cancer therapy
MX2018010546A (es) 2016-03-15 2019-02-20 Chugai Pharmaceutical Co Ltd Metodos de tratamiento de cancer que usan antagonistas de union al eje de muerte programada 1 (pd-1) y anticuerpos anti glipicano 3 (gpc3).
JP2019518713A (ja) 2016-03-16 2019-07-04 メリマック ファーマシューティカルズ インコーポレーティッド 癌療法のための改変ｔｒａｉｌ
KR102514317B1 (ko) 2016-04-15 2023-03-27 마크로제닉스, 인크. 신규 b7-h3-결합 분자, 그것의 항체 약물 콘쥬게이트 및 그것의 사용 방법
MX2018013072A (es) 2016-05-09 2019-03-21 Squibb Bristol Myers Co Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
UY37325A (es) 2016-07-14 2018-01-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Anticuerpos monoclonales que se enlazan a tim3 para estimular respuestas inmunitarias y composiciones que los contienen
MA45715A (fr) 2016-07-25 2019-05-29 Biogen Ma Inc Anticorps anti-hspa5 (grp78) et leurs utilisations
KR20190038607A (ko) 2016-08-02 2019-04-08 비스테라, 인크. 조작된 폴리펩티드 및 그의 용도
CN116251182A (zh) 2016-08-05 2023-06-13 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
SG11201900746RA (en) 2016-08-12 2019-02-27 Janssen Biotech Inc Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
GB201619652D0 (en) 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel polypeptides
BR112019010349A2 (pt) 2016-11-23 2019-10-08 Bioverativ Therapeutics Inc Anticorpos anti-fixa, anti-fxz e antifxa, molécula biespecífica, ácido nulceico, composiçãofarmacêutica e uso dos anteriores
WO2018139623A1 (en) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
CN110506057B (zh) 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
BR112019017695A2 (pt) 2017-02-28 2020-04-07 Bristol-Myers Squibb Company uso de anticorpos anti-ctla-4 com adcc acentuada para acentuar a resposta imune a uma vacina
SG11201907288RA (en) 2017-02-28 2019-09-27 Seattle Genetics Inc Cysteine mutated antibodies for conjugation
CN110709417B (zh) 2017-04-07 2023-10-31 美天施生物科技有限责任两合公司 具有突变人IgG4的多肽
US11767520B2 (en) 2017-04-20 2023-09-26 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
CN111094335B (zh) 2017-05-15 2022-08-23 罗切斯特大学 广泛中和的抗流感单克隆抗体及其用途
CN116333129A (zh) 2017-05-25 2023-06-27 百时美施贵宝公司 包含经修饰的重链恒定区的抗体
MX2019014576A (es) * 2017-06-05 2020-07-29 Janssen Biotech Inc Anticuerpos multiespecíficos manipulados genéticamente y otras proteínas multiméricas con mutaciones asimétricas en la región ch2-ch3.
US20200216542A1 (en) 2017-09-20 2020-07-09 Chugai Seiyaku Kabushiki Kaisha Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
US11230601B2 (en) 2017-10-10 2022-01-25 Tilos Therapeutics, Inc. Methods of using anti-lap antibodies
AU2018369639A1 (en) 2017-11-14 2020-04-23 Arcellx, Inc. D-domain containing polypeptides and uses thereof
KR20200087176A (ko) 2017-11-14 2020-07-20 아르셀엑스, 인크. 다기능성 면역 세포 요법
US20210087267A1 (en) 2017-12-20 2021-03-25 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-cd200 antibodies
WO2019126536A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Humanized anti-cd200 antibodies and uses thereof
CN111886255A (zh) 2018-01-12 2020-11-03 百时美施贵宝公司 抗tim3抗体及其用途
EP3743440A1 (en) * 2018-01-24 2020-12-02 Genmab B.V. Polypeptide variants and uses thereof
JP2018138022A (ja) * 2018-02-23 2018-09-06 ゲンマブ ビー．ブイ． ヒトＩｇＧ１ Ｆｃ領域変異体およびその使用
CN116327926A (zh) 2018-03-15 2023-06-27 中外制药株式会社 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
CN111971304A (zh) 2018-03-21 2020-11-20 戊瑞治疗有限公司 在酸性pH结合至VISTA的抗体
SG11202008767XA (en) 2018-03-23 2020-10-29 Bristol Myers Squibb Co Antibodies against mica and/or micb and uses thereof
CR20200450A (es) 2018-04-02 2021-02-11 Bristol Myers Squibb Co Anticuerpos anti-trem-l y usos de los mismos
EP3787678A1 (en) 2018-05-03 2021-03-10 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof
JP7372237B2 (ja) * 2018-06-04 2023-10-31 中外製薬株式会社 細胞質内での半減期が変化した抗原結合分子
SG11202100096XA (en) 2018-07-09 2021-02-25 Five Prime Therapeutics Inc Antibodies binding to ilt4
AU2019301120A1 (en) 2018-07-11 2021-02-25 Bristol-Myers Squibb Company Antibodies binding to VISTA at acidic pH
WO2020076969A2 (en) 2018-10-10 2020-04-16 Tilos Therapeutics, Inc. Anti-lap antibody variants and uses thereof
CN113348177A (zh) 2018-11-28 2021-09-03 百时美施贵宝公司 包含经修饰的重链恒定区的抗体
JP7536294B2 (ja) 2018-12-05 2024-08-20 株式会社バイカ・セラピュティクス 抗体のＦｃ領域改変体
WO2020118011A1 (en) 2018-12-06 2020-06-11 Alexion Pharmaceuticals, Inc. Anti-alk2 antibodies and uses thereof
EP3914622A1 (en) 2019-01-22 2021-12-01 Bristol-Myers Squibb Company Antibodies against il-7r alpha subunit and uses thereof
EP3943108A4 (en) 2019-03-19 2023-01-04 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE CONTAINING AN ANTIGEN-BINDING DOMAIN WHOSE ANTIGEN-BINDING ACTIVITY IS ALTERED DEPENDING ON THE MTA, AND BANK FOR OBTAINING SUCH ANTIGEN-BINDING DOMAIN
JP2022527372A (ja) 2019-04-08 2022-06-01 バイオジェン・エムエイ・インコーポレイテッド 抗インテグリン抗体及びそれらの使用
JP2022529939A (ja) 2019-04-18 2022-06-27 ブリストル－マイヤーズ スクイブ カンパニー 低ｐＨで結合するために特異性が増強されたイピリムマブバリアント
WO2021011678A1 (en) 2019-07-15 2021-01-21 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
EP3999541A1 (en) 2019-07-15 2022-05-25 Bristol-Myers Squibb Company Antibodies against human trem-1 and uses thereof
BR112022004831A2 (pt) 2019-09-19 2022-06-07 Bristol Myers Squibb Co Anticorpos que se ligam a vista em ph ácido
EP4126934A1 (en) 2020-04-01 2023-02-08 University of Rochester Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
KR20220161337A (ko) 2020-04-01 2022-12-06 쿄와 기린 가부시키가이샤 항체 조성물
WO2021207449A1 (en) 2020-04-09 2021-10-14 Merck Sharp & Dohme Corp. Affinity matured anti-lap antibodies and uses thereof
TW202216757A (zh) 2020-04-28 2022-05-01 美國洛克菲勒大學 中和性抗ｓａｒｓ－ｃｏｖ－２抗體及其使用方法
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
JP7048665B2 (ja) * 2020-05-22 2022-04-05 ゲンマブ ビー．ブイ． ヒトＩｇＧ１ Ｆｃ領域変異体およびその使用
US20230357341A1 (en) 2020-06-10 2023-11-09 Bica Therapeutics Inc. Fusion protein containing erythropoietin polypeptide
KR20230038522A (ko) * 2020-07-10 2023-03-20 인베티엑스 인코포레이티드 고양이에서 치료제의 반감기를 증가시키기 위한 조성물 및 사용 방법
WO2022098870A1 (en) 2020-11-04 2022-05-12 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
WO2022127793A1 (zh) 2020-12-18 2022-06-23 珠海泰诺麦博生物技术有限公司 呼吸道合胞病毒特异性结合分子
JP2024500920A (ja) 2020-12-23 2024-01-10 カンタージア アクチエボラーグ 抗ｉｌ１ｒａｐ抗体
EP4277926A1 (en) 2021-01-15 2023-11-22 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
WO2022212876A1 (en) 2021-04-02 2022-10-06 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
WO2022235867A2 (en) 2021-05-06 2022-11-10 The Rockefeller University Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
WO2023147399A1 (en) 2022-01-27 2023-08-03 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
WO2023191766A1 (en) * 2022-03-28 2023-10-05 Intervexion Therapeutics, Llc ANTIBODIES WITH ALTERED FcRn AFFINITY
US20240228664A9 (en) 2022-07-22 2024-07-11 Bristol-Myers Squibb Company Antibodies Binding to Human PAD4 and Uses Thereof
WO2024107749A1 (en) 2022-11-16 2024-05-23 Attralus, Inc. Fusion proteins that bind amyloid and the transferrin receptor and uses thereof

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5985599A (en) 1986-05-29 1999-11-16 The Austin Research Institute FC receptor for immunoglobulin
IL84285A (en) 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US4861579A (en) 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
GB8916400D0 (en) 1989-07-18 1989-09-06 Dynal As Modified igg3
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
WO1992007466A1 (en) 1990-11-05 1992-05-14 Bristol-Myers Squibb Company Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
GB9105245D0 (en) 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5550362A (en) 1992-11-20 1996-08-27 Intermec Corporation Method and apparatus for calibrating a bar code scanner
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5417972A (en) 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
GB9316989D0 (en) 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
WO1996004925A1 (en) 1994-08-12 1996-02-22 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
AU3968897A (en) 1996-08-02 1998-02-25 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
DE19721700C1 (de) 1997-05-23 1998-11-19 Deutsches Krebsforsch Mutierter OKT3-Antikörper
ES2190087T3 (es) 1997-06-13 2003-07-16 Genentech Inc Formulacion estabilizada de un anticuerpo.
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
DE69840412D1 (de) 1997-10-31 2009-02-12 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
PT1068241E (pt) 1998-04-02 2007-11-19 Genentech Inc Variantes de anticorpos e respectivos fragmentos
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
CN1320044A (zh) 1998-08-11 2001-10-31 Idec药物公司 包括施用抗－cd20抗体的b－细胞淋巴瘤联合疗法
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
DE69941903D1 (de) 1998-11-09 2010-02-25 Biogen Idec Inc Behandlung von patienten die eine knochenmarktransplantation oder eine transplantation peripherer blutstammzellen erhalten mit anti-cd20 antikörpern
PT2055313E (pt) 1998-11-09 2015-08-25 Biogen Idec Inc Tratamento de malignidades hematológicas associadas a células tumorais em circulação utilizando anticorpo quimérico anti-cd20
ATE384792T1 (de) 1998-11-18 2008-02-15 Genentech Inc Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
GB9900009D0 (en) * 1999-01-04 1999-02-24 Ml Lab Plc Gene therapy
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2359067C (en) 1999-01-15 2017-03-14 Genentech, Inc. Polypeptide variants with altered effector function
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
DK1176981T3 (da) 1999-05-07 2006-04-10 Genentech Inc Behandling af autoimmune sygdomme med antagonister som binder til B celleoverflademarkörer
KR20020020730A (ko) 1999-06-09 2002-03-15 오트리브 데이비스 더블유 Ｂ-세포를 표적하는 항체를 이용한 자가면역질환의 면역치료
ITMI991299A1 (it) 1999-06-11 2000-12-11 Consiglio Nazionale Ricerche Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
HUP0202238A3 (en) 1999-07-12 2004-05-28 Idec Pharmaceuticals Inc San D Blocking immune response to a foreign antigen using an antagonist which binds to cd20
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
EP1207906A4 (en) 1999-08-11 2005-07-06 Biogen Idec Inc TREATMENT OF NON-HODGKIN LYMPHOMA PATIENTS WITH BONE MARROW WITH INVOLVEMENT OF ANTI-CD20 ANTIBODIES
WO2001013945A1 (en) 1999-08-23 2001-03-01 Biocrystal Ltd. Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis
PT1265928E (pt) 2000-01-27 2010-09-30 Medimmune Llc Anticorpos neutralizantes com afinidade ultra-elevada
CN1406249B (zh) 2000-02-11 2010-06-16 默克专利股份有限公司 增加基于抗体的融合蛋白的循环半衰期
AU8729101A (en) 2000-03-31 2001-10-15 Idec Pharma Corp Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for the treatment of B cell lymphoma
CA2399940A1 (en) 2000-04-13 2001-10-25 The Rockefeller University Enhancement of antibody-mediated immune responses
AU2001259142C1 (en) 2000-04-25 2006-11-23 Biogen Idec Inc. Intrathecal administration of rituximab for treatment of central nervous system lymphomas
AU2001268363B2 (en) 2000-06-20 2006-08-17 Biogen Idec Inc. Treatment of B cell associated diseases
US20020128448A1 (en) 2000-10-20 2002-09-12 Idec Pharmaceuticals Corporation Variant IgG3 Rituxan and therapeutic use thereof
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2436092A1 (en) 2001-01-29 2002-08-08 Idec Pharmaceutical Corporation Modified antibodies and methods of use
CA2442801A1 (en) 2001-04-02 2002-10-10 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with gntiii
JP4679035B2 (ja) 2001-04-02 2011-04-27 ジェネンテック， インコーポレイテッド 併用療法
WO2003061694A1 (en) 2001-05-10 2003-07-31 Seattle Genetics, Inc. Immunosuppression of the humoral immune response by anti-cd20 antibodies
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US7151164B2 (en) 2002-02-14 2006-12-19 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003262650B2 (en) 2002-08-14 2009-10-29 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
EP2364996B1 (en) 2002-09-27 2016-11-09 Xencor Inc. Optimized FC variants and methods for their generation
DK3284753T3 (da) 2002-10-17 2021-07-05 Genmab As Humane monoklonale antistoffer mod cd20 til anvendelse i behandlingen af multipel sclerose
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
EP1587540B1 (en) 2003-01-09 2021-09-15 MacroGenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
ES2322267T3 (es) 2003-04-09 2009-06-18 Genentech, Inc. Terapia de una enfermedad autoinmunologica en un paciente que presenta una respuesta inadecuada a un inhibidor de tnf-alfa.
CN1802388B (zh) 2003-05-09 2011-01-05 杜克大学 Cd20特异抗体及使用它们的方法
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
TR201809892T4 (tr) 2003-11-05 2018-07-23 Roche Glycart Ag Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller.
US20050142133A1 (en) * 2003-12-03 2005-06-30 Xencor, Inc. Optimized proteins that target the epidermal growth factor receptor
UA86605C2 (ru) * 2004-01-12 2009-05-12 Аплайд Молекьюлер Иволюшн, Инк. Антитело, которое содержит вариант исходного человеческого fс-участка
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
BRPI0510674A (pt) 2004-07-15 2007-12-26 Xencor Inc variantes fc otimizadas
BRPI0514068B8 (pt) 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
SV2006002258A (es) 2004-10-08 2006-09-19 Wyeth Corp Inmunoterapia de trastornos autoinmunes
DK2325207T3 (en) 2004-11-12 2017-06-06 Xencor Inc Fc variants with altered binding to FcRn
FR2879204B1 (fr) 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
ZA200705459B (en) 2005-01-13 2008-09-25 Genentech Inc Treatment method
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
WO2006105338A2 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES

Also Published As

Publication number Publication date
JP5600697B2 (ja) 2014-10-01
WO2006020114A3 (en) 2006-04-06
AU2005274905B2 (en) 2010-12-23
BRPI0514068B1 (pt) 2018-11-27
DK1776384T3 (da) 2013-09-02
BRPI0514068A (pt) 2008-05-27
KR100864549B1 (ko) 2008-10-20
JP5055603B2 (ja) 2012-10-24
NO20071192L (no) 2007-03-05
MX2007001345A (es) 2008-03-11
KR20070038541A (ko) 2007-04-10
PL1776384T3 (pl) 2013-10-31
CN101001873A (zh) 2007-07-18
IL180885A0 (en) 2007-07-04
EP2213683A1 (en) 2010-08-04
ES2426817T3 (es) 2013-10-25
AU2005274905A1 (en) 2006-02-23
BR122018016031B8 (pt) 2021-07-27
BRPI0514068B8 (pt) 2021-05-25
JP2012136541A (ja) 2012-07-19
CA2573192C (en) 2013-09-10
NO339556B1 (no) 2017-01-02
DK2213683T3 (da) 2013-09-02
ES2426816T3 (es) 2013-10-25
US7740847B2 (en) 2010-06-22
US20070224188A1 (en) 2007-09-27
WO2006020114A2 (en) 2006-02-23
CA2779559A1 (en) 2006-02-23
JP2008511292A (ja) 2008-04-17
CN101001873B (zh) 2013-03-13
EP1776384B1 (en) 2013-06-05
CA2573192A1 (en) 2006-02-23
EP1776384A2 (en) 2007-04-25
BR122018016031B1 (pt) 2019-10-22
PL2213683T3 (pl) 2013-10-31
EA012464B1 (ru) 2009-10-30
EP2213683B1 (en) 2013-06-05

Similar Documents

Publication Publication Date Title
EA200700210A1 (ru) ВАРИАНТЫ ОБЛАСТИ Fc
NL301089I2 (nl) imlifidase
WO2006066024A3 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
NO20071419L (no) Polypeptidvarianter med endret effektorfunksjon
WO2004078778A3 (en) PEPTIDES THAT SPECIFICALLY BIND HGF RECEPTOR (cMet) AND USES THEREOF
GB2430677A8 (en) Novel antigenbinding polypeptides and their uses
WO2005077981A3 (en) Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
MX341370B (es) Antagonistas anti - beta7 humanizados y usos para los mismos.
WO2004041865A3 (en) Stabilized single domain antibodies
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
WO2007019865A3 (en) Therapy with cd4 binding peptides and radiation
WO2006054096A3 (en) Soluble bifunctional proteins
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
EA200801180A1 (ru) Селективные пептидные агонисты рецептора vpac2
EA200800301A1 (ru) Протеины, связывающие il-6
EA200702193A1 (ru) Гликозилирование белков
EA200800535A1 (ru) Пептиды и соединения, которые связываются с рецептором
ATE537186T1 (de) P53-bindendes polypeptid
AU2002345804A1 (en) Antimicrobially active peptide
EA200702353A1 (ru) Белковые гидролизаты, снижающие кровяное давление
ATE452650T1 (de) Transferrin-fusionsproteinbibliotheken
WO2005037236A3 (en) Novel heat shock protein 20-related polypeptides and uses therefor
WO2003091383A3 (fr) Epitopes t de l'antigene epha2.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment